LATEST NEWS
March 24, 2026: ‘Radiance Biopharma speaking at Miami Global Family Office Investment Summit‘ – EINPresswire
February 4, 2026: ‘Radiance Biopharma invited speaker at Global Family Office Investment Summit‘ – EINPresswire
Radiance Biopharma’s mission is to develop a pipeline of next generation cancer therapies and drugs for other high unmet medical needs.
Radiance’s Board of Directors, Management and Advisors are industry veterans with experience in both large pharma and biotechnology startups and are committed to transforming the lives of patients with cancer.
RB-undisclosed
RB-203 is a proprietary monoclonal antibody recognizing membrane Hsp70 which is expressed on the majority of tumors, but not normal cells. Learn more